iwNHL 2025 | Could trispecific antibodies reduce the need for combination regimens in lymphoma?

Combination regimens are often the way that we best target patients with lymphoma, and that’s because targeting one antigen with one drug is a way that sometimes lymphomas will evolve or develop resistance. And so usually antibodies, like bispecific antibodies, are best served as a combination with a different drug that can co-treat the disease, therefore reducing the risk that the treatment fails. Trispecific antibodies are in some sense a combination partner in themselves, that they have two ways to bind to the cancer cell, and so almost two drugs in the same antibody. So theoretically, they are already a combination approach in ways that bispecifics are not. It’s unclear if that will pan out that they are combination-level effective compared to a bispecific antibody. Are they significantly better? Or is this T-cell targeting therapy similar in terms of whether you target two or three or even more antigens, or are you kind of maxing out the benefit of a T-cell directed therapy? I think theoretically, trispecific antibodies should be advantageous as a combination strategy, meaning that they already have that combination built in. Plus, you could combine them with other drugs, just like bispecifics could. So they’re kind of a built-in combo, but they could also have other drugs added to them to further improve their efficacy.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.